These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16633862)

  • 1. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
    Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
    Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efalizumab: integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis.
    Lynde C
    J Cutan Med Surg; 2006; 9 Suppl 1():1-3. PubMed ID: 16633863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
    Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
    J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
    Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
    Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efalizumab: a biological agent for the treatment of psoriasis.
    Hodulik S; Hadi S
    Rev Recent Clin Trials; 2006 May; 1(2):165-8. PubMed ID: 18473968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbation of psoriasis under efalizumab therapy.
    Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
    J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efalizumab].
    Descamps V
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.
    Jullien D; Prinz JC; Langley RG; Caro I; Dummer W; Joshi A; Dedrick R; Natta P
    Dermatology; 2004; 208(4):297-306. PubMed ID: 15178911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
    Cather JC; Cather JC; Menter A
    Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
    Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
    Vugmeyster Y; Kikuchi T; Lowes MA; Chamian F; Kagen M; Gilleaudeau P; Lee E; Howell K; Bodary S; Dummer W; Krueger JG
    Clin Immunol; 2004 Oct; 113(1):38-46. PubMed ID: 15380528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The lymphocyte: protagonism in the new era of the biological therapies].
    Gutiérrez M; Ruiz Carrascosa JC
    Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():2-8. PubMed ID: 18341848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG; Ho V; Lynde C; Papp KA; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():18-25. PubMed ID: 16633860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efalizumab-associated papular psoriasis.
    Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
    Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse, rebound, and psoriasis adverse events: an advisory group report.
    Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hand and foot psoriasis with emphasis on efalizumab.
    Kircik L
    Skin Therapy Lett; 2007 Nov; 12(9):4-7. PubMed ID: 18087658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efalizumab modulates T cell function both in vivo and in vitro.
    Koszik F; Stary G; Selenko-Gebauer N; Stingl G
    J Dermatol Sci; 2010 Dec; 60(3):159-66. PubMed ID: 21044829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.